Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
March 30, 2022 16:01 ET
|
Centessa Pharmaceuticals plc
– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022...
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
March 23, 2022 16:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim...
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
March 07, 2022 07:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to...
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
February 24, 2022 07:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today...
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application
December 14, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the...
Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
December 13, 2021 16:15 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to...
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
November 15, 2021 07:00 ET
|
Centessa Pharmaceuticals plc
~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate...
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
November 10, 2021 16:45 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the...
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
November 01, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~ ...
Дочерняя компания Centessa Pharmaceuticals, Orexia Therapeutics и Schrödinger объявляют о сотрудничестве для открытия новых агонистов рецепторов орексина
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ Исследования будут сосредоточены на малых молекулах с дифференцированными клиническими профилями, чтобы использовать широкий потенциал агонизма орексина по разным показаниям ~ ~ Впервые Schrödinger...